Noah Editorial
Blog
Timely research perspectives, biotech market signals, and clinical updates in a cleaner long-form reading format.
September 24, 2026
•ComparisonSevere Asthma Indication Strategy Report 2026: TSLP Biology, Clinical Competition and Development Strategy
A 2026 severe asthma strategy report covering TSLP biology, unmet need, clinical validation, biologic competition, biomarker segmentation, and development strategy.
By Linda
September 24, 2026
•Comparison10 Biopharma Drugs to Watch in 2026: Regulatory Milestones, Phase 3 Readouts and What Comes Next
Track 10 biopharma drugs shaping 2026 through FDA and EC approvals, regulatory reviews, sponsor-reported Phase 3 topline results, launch milestones, and the next major catalysts.
By Linda
September 24, 2026
•How-toThe RAS Revolution in Pancreatic Cancer 2026: Targeted Therapy, Combination Strategies and Prevention
A 2026 review of RAS-targeted therapy in pancreatic cancer covering daraxonrasib, KRAS G12D and G12V strategies, phase 3 outcomes, combination therapy, synthetic lethality, and cancer interception.
By Linda
September 24, 2026
•How-toAI Agents for Biomedical Research: How Noah Turns Medical Evidence Into Research Workflows
Learn how Noah supports biomedical research workflows with PubMed Search, Health Search, multi-step Agent research, evidence synthesis, and structured cited outputs.
By Linda
September 22, 2026
•Use CasesCyclic Peptides in Drug Discovery 2026: Structures, Oral Bioavailability and Clinical Landscape
Explore cyclic peptide drug discovery in 2026, from cyclization chemistry and oral bioavailability to AI design, target opportunities, and the clinical pipeline.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Eligibility Criteria Comparison (2026)
Compare AI tools for clinical trial eligibility criteria analysis, with a real Noah AI case across RASolute 305, 3082-CL-0301, and DAWN-303 in KRAS G12D metastatic pancreatic cancer.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Patient Population Comparison (2026)
Compare AI tools for clinical trial patient population analysis, with a real Noah AI case across DESTINY-Breast03, Breast04, and Breast06.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Drug Class Comparison (2026)
Compare AI tools for drug class analysis, with a real Noah AI workflow comparing SGLT2 inhibitors and GLP-1 receptor agonists.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Indication Expansion Research (2026)
Compare AI tools for indication expansion research, with a real Noah AI case evaluating Enhertu from previously treated to first-line HER2-mutant NSCLC.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Medical Evidence Gap Analysis (2026)
Learn how to identify medical evidence gaps with Noah AI — separating established evidence from open questions, methodological limits, and ongoing trials — using a real 2026 TNBC pembrolizumab case.
By Linda
September 22, 2026
•Use CasesMASH Indication Strategy Report 2026: Epidemiology, Target Biology, Clinical Competition and Deal Outlook
A 2026 MASH indication strategy report covering epidemiology, fibrosis-stage opportunity, THR-beta vs FGF21, late-stage competition, deal activity and entry strategy.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Drug Safety Evidence Review (2026)
Compare the best AI tools for drug safety evidence review. We test Noah AI on T-DXd and ILD/pneumonitis to show how regulatory, trial, and real-world evidence fit together.
By Linda